Sanofi and Translate Bio Have a COVID-19 Vaccine Candidate Ready for Clinical Trials
Sanofi (NASDAQ: SNY) has a new COVID-19 vaccine candidate ready to start clinical trials in humans. On Thursday, it reported that MRT5500, which was discovered by Translate Bio (NASDAQ: TBIO), induced antibodies to the coronavirus in mice and nonhuman primates. The vaccine also induced a T cell response.
MRT5500 is a messenger RNA (mRNA) vaccine candidate, similar to the candidates being developed by Moderna and the Pfizer/BioNTech collaboration. Using mRNA in vaccines is a new technology and as yet, no mRNA vaccines for any conditions have been approved by the FDA.
Image source: Getty Images
Source Fool.com
